L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer

Objective The aim was to study the association of L1 cell adhesion molecule (L1CAM) expression with the outcome of patients with endometrial cancer, especially with regard to conventional risk variables, and to compare the patterns of relapse in L1CAM-positive and -negative cancers. Methods This was a retrospective study of 805 women. The Kaplan–Meier method and univariate and multivariate Cox regression models were applied for survival analyses. Missing data were replaced using multiple imputation. The median follow-up time was 51 months (range, 1–98). Results One hundred twenty-one (15.0%) cases were L1CAM positive. L1CAM positivity was associated with high stage (I vs II–IV) (odds ratio [OR], 2.3), lymph node involvement (OR, 2.9), poor differentiation (OR, 6.1), non-endometrioid histology (OR, 9.9), lymphovascular space invasion (OR, 2.8), cervical stromal invasion (OR, 1.8), positive peritoneal cytology (OR, 4.1), and age older than 65 years (OR, 2.8). The frequencies of deep myometrial invasion (50% or deeper), tumor size 2 cm or greater, and body mass index 30 kg/m2 or greater were not significantly different between L1CAM-positive and -negative cases. L1CAM predicted poor disease-specific survival in endometrioid (P < 0.0001) but not in non-endometrioid carcinomas (P = 0.934). The negative impact of L1CAM on outcome was confirmed in a Cox multivariate disease-specific survival analysis. Univariate survival analyses in the different ESMO–ESGO–ESTRO endometrial cancer risk groups showed an association between L1CAM positivity and poor outcome in intermediate (hazard ratio, 12) and high-risk advanced metastatic (hazard ratio, 2.0) groups. Extra-abdominal relapses were more frequent in L1CAM-positive (13.2%) than L1CAM-negative (1.9%) stage I endometrioid carcinomas (P < 0.0001), whereas other site-specific relapses in local cancers were L1CAM independent. Conclusions L1CAM is associated with the occurrence of poor prognostic variables and predicts advanced disease in endometrial cancer. L1CAM predicts extra-abdominal relapses and poor survival in endometrioid endometrial cancer, but seems not to be a prognostic factor in non-endometrioid carcinomas.

[1]  T. Herzog,et al.  Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. , 2011, American journal of obstetrics and gynecology.

[2]  P. Altevogt,et al.  L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. , 2013, Journal of the National Cancer Institute.

[3]  Jason D. Wright,et al.  Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. , 2013, Gynecologic oncology.

[4]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[5]  P. Goodfellow,et al.  Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.

[6]  P. Altevogt,et al.  Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. , 2012, Cancer letters.

[7]  P. Altevogt,et al.  L1CAM in human cancer , 2016, International journal of cancer.

[8]  A. Rademaker,et al.  Tumor size in endometrial cancer , 1991, Cancer.

[9]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[10]  V. Hasselblad,et al.  Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. , 2016, Gynecologic oncology.

[11]  F. Clavel-Chapelon,et al.  A suggested modification to FIGO stage I endometrial cancer. , 2014, Gynecologic oncology.

[12]  P. Altevogt,et al.  Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells , 2007, Oncogene.

[13]  M. Frotscher,et al.  Role of L1CAM for axon sprouting and branching , 2012, Cell and Tissue Research.

[14]  V. Torri,et al.  Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. , 2014, American journal of obstetrics and gynecology.

[15]  T. Bosse,et al.  L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.

[16]  P. Altevogt,et al.  L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. , 2007, Gynecologic oncology.

[17]  T. Herzog,et al.  Endometrial cancer: a review and current management strategies: part II. , 2014, Gynecologic oncology.

[18]  Jason D. Wright,et al.  Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. , 2011, Obstetrics and gynecology.

[19]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[20]  T. Herzog,et al.  Endometrial cancer: a review and current management strategies: part I. , 2014, Gynecologic oncology.

[21]  P. Altevogt,et al.  L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas , 2003, The Lancet.

[22]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[23]  M. Carey,et al.  Are Uterine Risk Factors More Important Than Nodal Status in Predicting Survival in Endometrial Cancer? , 2009, Obstetrics and gynecology.

[24]  J. van der Velden,et al.  Validation of tissue microarray technology in endometrioid cancer of the endometrium , 2006, Journal of Clinical Pathology.

[25]  C. Ouyang,et al.  L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). , 2016, Gynecologic oncology.

[26]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[27]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[28]  J A Blessing,et al.  Surgical Staging in Endometrial Cancer: Clinical—Pathologic Findings of a Prospective Study , 1984, Obstetrics and gynecology.

[29]  Practice Bulletin No. 149: Endometrial Cancer , 2015, Obstetrics and gynecology.

[30]  H. Salvesen,et al.  Current Status of Molecular Biomarkers in Endometrial Cancer , 2014, Current Oncology Reports.

[31]  A. Leminen,et al.  Combined use of endometrial sample and magnetic resonance imaging in the preoperative risk‐stratification of endometrial carcinomas , 2015, Acta obstetricia et gynecologica Scandinavica.